Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s traded shares stood at 0.74 million during the last session, with the company’s beta value hitting 1.48. At the close of trading, the stock’s price was $6.29, to imply a decrease of -2.33% or -$0.15 in intraday trading. The ADPT share’s 52-week high remains $7.07, putting it -12.4% down since that peak but still an impressive 63.75% since price per share fell to its 52-week low of $2.28. The company has a valuation of $928.27M, with an average of 1.12 million shares in intraday trading volume over the past 10 days and average of 1.19 million shares over the past 3 months.
Analysts have given a consensus recommendation of Hold for Adaptive Biotechnologies Corp (ADPT), translating to a mean rating of 1.50. Of 11 analyst(s) looking at the stock, 1 analyst(s) give ADPT a Sell rating. 0 of those analysts rate the stock as Overweight while 6 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.24.
Adaptive Biotechnologies Corp (NASDAQ:ADPT) trade information
After registering a -2.33% downside in the last session, Adaptive Biotechnologies Corp (ADPT) has traded red over the past five days. The 5-day price performance for the stock is 4.83%, and 10.74% over 30 days. With these gigs, the year-to-date price performance is 28.37%. Short interest in Adaptive Biotechnologies Corp (NASDAQ:ADPT) saw shorts transact 9.58 million shares and set a 6.68 days time to cover.
The extremes give us $5 and $18 for target low and target high price respectively. As such, ADPT has been trading -186.17% off suggested target high and 20.51% from its likely low.
Adaptive Biotechnologies Corp (ADPT) estimates and forecasts
Looking at statistics comparing Adaptive Biotechnologies Corp share performance against respective industry, we note that the company has outperformed competitors. Adaptive Biotechnologies Corp (ADPT) shares are 73.76% up over the last 6 months, with its year-to-date growth rate higher than industry average at 18.84% against 16.60%. The rating firms project that company’s revenue will grow 4.34% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 45.84M. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 46.32M.Earnings reports from the last fiscal year show that sales brought in 45.78M and 41.87M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 0.13% before jumping 10.62% in the following quarter.
ADPT Dividends
Adaptive Biotechnologies Corp has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s Major holders
Adaptive Biotechnologies Corp insiders hold 1.93% of total outstanding shares, with institutional holders owning 93.92% of the shares at 95.77% float percentage. In total, 93.92% institutions holds shares in the company, led by VIKING GLOBAL INVESTORS LP. As of 2024-06-30, the company held over 29.99 million shares (or 20.5736% of shares), all amounting to roughly $108.58 million.
The next major institution holding the largest number of shares is RUBRIC CAPITAL MANAGEMENT LP with 14.0 million shares, or about 9.603% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $50.68 million.
We also have ARK ETF Tr-ARK Genomic Revolution ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Adaptive Biotechnologies Corp (ADPT) shares. Going by data provided on Oct 31, 2024 , ARK ETF Tr-ARK Genomic Revolution ETF holds roughly 11.26 shares. This is just over 7.63% of the total shares, with a market valuation of $70.8 million. Data from the same date shows that the other fund manager holds a little less at 4.19, or 2.84% of the shares, all valued at about 26.37 million.
